Original-Research: DO & CO AG (von NuWays AG): BUY
Source: EQS
Classification of
Q1 defies travel fears, growth continues across all segments Q1 revenues increased by 11% yoy to € 612m, driven by growth across all segments: Q1 marked a new EBIT record as it expanded by 44% yoy to € 53m (8.6% margin, up 2pp yoy and 0.1pp qoq). Generally speaking, the main driver was the improved gross margin (+2pp yoy) mainly thanks a relative cost reduction in AC (JFK ramp up costs in Q1’24/25). Out of the absolute € 16m yoy EBIT increase on group level, € 13.1m yoy came from AC (16% incremental EBIT margin), € 1.2m yoy came from IEC (13% incremental EBIT margin) and € 1.6m yoy came from RLH (49% incremental EBIT margin) highlighting the strong margin profile in this segment. On group level, Q1 thus showed a 26% incremental EBIT margin, highlighting the profitability gains stemming from a low fixed cost ratio coupled with revenue growth. On the back of the developments described above, cash generation improved drastically on a yoy comparison. CFO went up by € 20m or 156% yoy to € 32.5m on the back of higher earnings and slightly lower tie up in working capital. Secondly, investments nearly halved from € 18.5m (Q1 24/25) to € 9.6m, resulting in an excellent FCF of € 23m (vs. € -5.8m in Q1’24/25). Against prior fears of slowing demand, DOC is experiencing the opposite and thus reiterated its FY’25/26 guidance of 8-10% sales growth but specified the EBIT margin target to the upper end of 8.0-8.5%. In the mid-term, a continuous momentum is expected (8-10% sales growth annually, € 3bn sales within the next years) with continuously expanding margins due to operating leverage. Against this backdrop, we adapt our assumptions to reflect a better than expected profitability and demand curve into the following years. In effect, we therefore increase our DCF-based PT to € 266 (old: € 235) and confirm the BUY recommendation. You can download the research here: do-co-ag-2025-08-15-update-en-006b2 For additional information visit our website: https://www.nuways-ag.com/research-feed Contact for questions: Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 ++++++++++ Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, |
2184366 15.08.2025 CET/CEST